A nurse is caring for a client in the emergency department who has a preliminary diagnosis of a transient ischemic attack (TIA). Which of the following diagnostic testing should the nurse anticipate the provider to prescribe?

A. Intellectual capacity is not affected:

This statement refers to the fact that ALS primarily affects motor neurons, leading to muscle weakness and paralysis, but it typically does not directly impact cognitive function or intellectual capacity. While cognitive impairment is not a hallmark feature of ALS, some individuals may experience changes in cognitive function or behavior, such as executive dysfunction or frontotemporal dementia, in later stages of the disease. However, depression in ALS is not primarily linked to changes in intellectual capacity but rather to other factors such as altered communication, physical limitations, and loss of autonomy.

B. Communication is altered:

ALS can affect the muscles involved in speech and swallowing, leading to difficulties in communicationAs the disease progresses, patients may experience dysarthria (difficulty speaking clearly) and dysphagia (difficulty swallowing), which can impair their ability to communicate effectively with others. Altered communication can result in frustration, social isolation, and feelings of being misunderstood, all of which are risk factors for depression.

C. Mobility is limited:

ALS causes progressive muscle weakness and paralysis, which can significantly impair mobility over time. As the disease advances, individuals with ALS may become increasingly dependent on mobility aids such as wheelchairs or may require assistance with mobility tasks. Limited mobility can lead to feelings of loss of independence, decreased participation in activities, and increased dependence on caregivers, all of which can contribute to depression.

D. Nutritional intake is poor:

ALS can affect the muscles involved in swallowing and chewing, leading to difficulties with eating and drinking. Dysphagia, or difficulty swallowing, is a common symptom in ALS and can result in poor nutritional intake and weight loss. Malnutrition and weight loss are associated with increased morbidity and mortality in ALS, and they can also contribute to feelings of weakness, fatigue, and overall decline in quality of life, which may exacerbate depression.

A. Hyperglycemia:

Hyperglycemia refers to high blood sugar levels. While certain medications can affect glucose metabolism and potentially lead to hyperglycemia as a side effect, this is not typically associated with hydantoin therapy for seizure disorder. Therefore, it is less likely for the patient to experience hyperglycemia as a direct result of taking hydantoin medication.

B. Hunger:

Hunger is not a common side effect of hydantoin therapy for seizure disorder. While some medications may affect appetite or cause changes in eating habits, hunger is not a typical side effect of hydantoin medications such as phenytoin.

C. Hypoglycemia:

Hypoglycemia refers to low blood sugar levels, which can lead to symptoms such as confusion, dizziness, sweating, and weakness. Hydantoin medications, particularly phenytoin, can affect glucose metabolism and increase the risk of hypoglycemia, especially in patients who already have diabetes or are prone to low blood sugar. Therefore, it is important for patients taking hydantoin therapy to monitor their blood sugar levels regularly and be aware of the signs and symptoms of hypoglycemia.

D. Pupil dilation:

Pupil dilation, or mydriasis, is not a common side effect of hydantoin therapy for seizure disorder. While certain medications may affect pupil size, this is not typically associated with hydantoin medications such as phenytoin.